IQ3
CAS No. 312538-03-7
IQ3( —— )
Catalog No. M22014 CAS No. 312538-03-7
IQ3 is a selective inhibitor of JNK3(JNK3, JNK1 and JNK2 with Kd of 66 nM, 240 nM and 290 nM, respectively).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 69 | Get Quote |
|
| 10MG | 105 | Get Quote |
|
| 25MG | 208 | Get Quote |
|
| 50MG | 332 | Get Quote |
|
| 100MG | 494 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameIQ3
-
NoteResearch use only, not for human use.
-
Brief DescriptionIQ3 is a selective inhibitor of JNK3(JNK3, JNK1 and JNK2 with Kd of 66 nM, 240 nM and 290 nM, respectively).
-
DescriptionIQ3 is a selective inhibitor of JNK3(JNK3, JNK1 and JNK2 with Kd of 66 nM, 240 nM and 290 nM, respectively). IQ 3 inhibits NF-κB/AP1 transcriptional activity in THP1-Blue cells with IC50 of 1.4 μM, also inhibits TNF-α and IL-6 production in vitro.
-
In VitroIQ-3 exhibits IC50 of 2.2 μM (TNF-α in human monoMac-6 cells), 1.5 μM (IL-6 in human monoMac-6 cells), 4.7 μM (TNF-α in human PBMCs), 9.1 μM (IL-6 in human PBMCs) and 6.1 μM (NO in murine J774.A1), respectively.IQ-3 exhibits an IC50 of 1.4 μM for inhibiting LPS-induced NF-κB/AP-1 transcriptional activity in human THP-1 Blue monocytic cells.IQ-3 is indeed a competitive inhibitor for the ATP binding site of JNK3. Cell Viability Assay Cell Line:PBMCs.Concentration:0-80 μM (200 ng/mL LPS).Incubation Time:30 min.Result:Downregulated TNF-α concentration (IC50 = 4.7 μM).
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
TargetJNK
-
RecptorJNK3|JNK1|JNK2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number312538-03-7
-
Formula Weight341.32
-
Molecular FormulaC20H11N3O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (73.25 mM)
-
SMILESO=C(ON=C1C2=CC=CC=C2C2=NC3=CC=CC=C3N=C12)C1=CC=CO1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Schepetkin I A , Kirpotina L N , Khlebnikov A I , et al. Identification and Characterization of a Novel Class of c-Jun N-terminal Kinase Inhibitors[J]. Molecular Pharmacology, 2012, 81(6):832-845.
molnova catalog
related products
-
AS601245
A potent and selective inhibitor of JNK with IC50s of 70/220/150 nM for JNK1/2/3 respectively.
-
c-JUN peptide
Peptide comprising residues 33 - 57 of the JNK binding (δ) domain of human c-Jun. Disrupts JNK/c-Jun interaction leading to inhibition of serum-induced c-Jun phosphorylation, up-regulation of p21cip/waf and modulation of inflammatory gene expression. Specifically induces apoptosis in HeLa tumor cells.
-
JNK-IN-8
JNK-IN-8 is a potent, selective, pan-JNK inhibitor with IC50 of 4.7 nM, 18.7 nM and 1 nM for JNK1, JNK2 and JNK3, respectively.
Cart
sales@molnova.com